Drug’s unique mechanism of action targets schizophrenia abnormalities
Drug Discovery World
JULY 5, 2024
Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS). The drug’s unique mechanism of action targets the core abnormalities in patients with schizophrenia and reduces hippocampal dopaminergic activity, improving symptoms of psychosis, social interactions and cognition.
Let's personalize your content